NCT01497392View on ClinicalTrials.gov

Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

March 29, 2012

Primary Completion Date

August 31, 2015

Study Completion Date

February 7, 2017

Conditions
Adenocarcinoma of the PancreasStage III Pancreatic CancerStage IV Pancreatic CancerUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

dovitinib lactate

Given PO

DRUG

gemcitabine hydrochloride

Given IV

DRUG

capecitabine

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

enzyme-linked immunosorbent assay

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER